Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) issued an announcement. Recently, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. (“Fosun Wanbang”), a holding subsidiary of the company, received approval from the State Drug Administration to conduct clinical trials for the treatment of signs and symptoms of idiopathic Parkinson's disease in adults. Fosun Wanbang plans to conduct phase I clinical trials of this drug in China when conditions are met. This drug is a chemical drug. According to the latest IQVIA CHPA data, in 2025, sales of drugs with the same compound in China will be approximately 375 million yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.